Rick Simpson Oil (RSO) in Montezuma County, Colorado: The Complete Guide by OilWell Cannabis

If you’re in Montezuma County searching for real answers about Rick Simpson Oil, you’ve landed in the right place. Whether you’re in Cortez tending crops under these big southwestern skies, a veteran in Dolores managing PTSD, or a caregiver in Mancos supporting someone through cancer treatment, we wrote this for you. Montezuma County isn’t just a dot on the map to us—it’s a community of resilient people who deserve honest cannabis education, not hype. Let’s talk about what RSO actually is, what the science really says, and how our formulas might fit into your life here in the Four Corners.

About Rick Simpson and Traditional RSO

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor or scientist—he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began when the medical system failed him. In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. He reported that prescribed medications either failed to help or made his condition worse. When he asked his physician about cannabis, the request was refused.

Simpson’s interest in concentrated cannabis oil deepened after learning about a 1974 NIH-funded study at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a reference point for Simpson, though its findings were never replicated in controlled human cancer trials.

The pivotal moment came in 2003 when Simpson claimed three bumps on his arm were diagnosed as basal cell carcinoma. Rather than conventional treatment, he applied concentrated cannabis oil directly to the lesions, covered them with bandages, and reported they disappeared within four days. No independent medical verification has ever been published—no biopsy confirmation, no clinical follow-up in any peer-reviewed source. This personal experience became the origin story of Rick Simpson Oil.

Important context: Simpson’s account is personal testimony, not medical evidence. These events cannot be evaluated as clinical proof, but they are historically significant as the catalyst for a global movement.

The crusade — spreading the oil

After 2003, Simpson committed himself to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community—no charge, no profit. By his account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and more.

His story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film became foundational in cannabis communities—many people’s first introduction to concentrated cannabis oil as medicine.

Simpson’s advocacy brought him into conflict with Canadian law. The RCMP raided his property in 2005 and 2009, seizing plants and equipment. He was charged with cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada for Europe, living in Croatia and later the Netherlands, continuing his advocacy from abroad.

In 2012, he published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his primary platform.

Throughout his public career, Simpson maintained that cannabis oil—particularly high-THC oil made his way—could cure cancer and many other diseases. He claimed pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect financial interests.

Important context: Simpson’s conspiratorial framing reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance. We present it without endorsement or dismissal.

The traditional RSO protocol

Simpson’s core recommendation was a structured oral protocol: 60 grams of concentrated cannabis oil over approximately 90 days. Here’s the detailed breakdown:

Goal

Consume 60 grams of high-THC cannabis oil over roughly 90 days. Simpson considered this the minimum for serious cancer treatment.

Titration schedule

• Week 1: Half a grain of rice-sized dose (10-15 mg) three times daily—total daily intake: 30-45 mg
• Weeks 2-5: Double the dose every four days to build tolerance gradually, reaching approximately 1 gram (1,000 mg) per day by week 5, divided into three roughly equal doses of ~333 mg each
• Weeks 5-12: Maintain 1 gram per day until all 60 grams are consumed

Administration methods

• Oral (primary): Sublingual or swallowed—for systemic absorption and internal cancers
• Topical (secondary): Applied directly to skin cancers with bandages, changed every 3-4 days
• Inhalation (not recommended as primary): For immediate symptom relief only—not considered therapeutically essential for the protocol

Tolerance and psychoactive effects

• Simpson claimed patients develop tolerance to THC’s psychoactive effects within 3-4 weeks
• He recommended initial nighttime dosing to sleep through the most intense effects
• Warned against driving or operating machinery during titration

Post-protocol maintenance

After completing the 60-gram course, Simpson recommended 1-2 grams per month indefinitely for long-term health and cancer prevention.

Important context for evaluating this protocol

• No controlled trial validation: No published randomized controlled trials, cohort studies, or well-documented case series evaluate this specific protocol
• Crude, unstandardized material: Assumes single-strain, THC-dominant extract with no standardized potency
• Very high THC exposure: At peak dosing, patients consume roughly 1 gram of high-THC oil daily. Assuming 60-90% THC content, that’s 600-900 mg of delta-9 THC per day—far exceeding anything studied in controlled settings (FDA-approved dronabinol is typically 2.5-20 mg/day)
• Real risks at these doses: Severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder are well-documented at such high doses
• Oncology context: Patients with active cancer are medically complex. Using unregulated, unstandardized cannabis oil as primary treatment—potentially in place of proven therapies—introduces serious harm risk

What is traditional Rick Simpson Oil—the product

Source material

High-THC, indica-dominant cannabis strains. No strain standardization—starting material varied by availability and growing season.

Extraction solvent

Naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol—neither food-grade. Naphtha may contain benzene, toluene, and other toxic/carcinogenic compounds.

Extraction process

1. Cannabis material placed in bucket
2. Covered with solvent and agitated to dissolve cannabinoids
3. Poured through filter into collection vessel
4. Repeated with fresh solvent
5. Combined solvent washes placed in rice cooker
6. Solvent evaporated at heat sufficient to decarboxylate THCa and destroy terpenes
7. Thick, dark oil remains
8. Transferred to oral syringes

Appearance and physical characteristics

Nearly black, thick, viscous, tar-like oil with strong cannabis odor and possible solvent-residual smell. Difficult to handle at room temperature.

Cannabinoid profile

• Fully decarboxylated delta-9 THC (60-90% estimated)
• Naturally occurring minor cannabinoids at uncontrolled ratios
• No ability to adjust or standardize specific ratios

Terpene content

Minimal to none—destroyed by solvent extraction and high-heat evaporation.

Standardization and testing

None. Every batch differed. No Certificate of Analysis, no cannabinoid quantification, no contaminant screening.

Residual solvent risk

Significant. Naphtha may contain toxic compounds. Incomplete purging is difficult to verify without lab testing.

Simpson’s claims vs. the evidence record

Simpson claimed RSO could cure cancer and many other diseases. Let’s evaluate this against actual evidence.

What Simpson was not

He was not a scientist, physician, pharmacologist, or researcher. He had no formal medical training, never conducted or published a clinical trial, never submitted results to peer review. His evidence base consisted entirely of personal experience and testimonials—no controls, no independent verification, no long-term follow-up.

What the preclinical literature shows

• In vitro studies demonstrate THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines
• Animal models show some tumor-growth inhibition
• These findings generate scientific interest but have not translated to proven human cancer cures

What the preclinical literature does not show

• No human clinical trial has demonstrated RSO or any cannabis oil cures cancer
• The gap between animal/in vitro results and human outcomes is vast
• Small human trials in glioblastoma have been exploratory and haven’t produced cure-level results

Institutional positions

• National Cancer Institute (NCI): Acknowledges cannabinoid anticancer research in lab/animal models but does not endorse cannabis as cancer treatment
• FDA: Has not approved any cannabis plant product for cancer treatment. Only Epidiolex (CBD) for seizures and dronabinol/nabilone for chemo nausea/AIDS wasting are approved
• Health Canada: Never approved RSO or cannabis oil as cancer cure
• NCCIH: Strongest evidence is for rare epilepsies, chemo nausea, and HIV/AIDS appetite—not cancer cure

What Simpson got right

He drew attention to cannabinoids as serious biomedical research when the world ignored it. His advocacy helped create conditions for the legal cannabis industry. The term “RSO” remains the most recognized name for full-spectrum cannabis extract.

What he overstated

The leap from preclinical signals to cancer cure wasn’t supported by human evidence then and isn’t now. Encouraging patients to rely on RSO instead of proven oncologic therapies carries genuine harm potential. Delayed treatment for treatable cancers is a documented concern.

The legacy of Rick Simpson and modern RSO evolution

The term “RSO” is now used broadly and loosely across the legal cannabis industry. Many products labeled RSO bear little resemblance to Simpson’s original oil. The term has become generic.

Simpson has been critical of commercial products using the RSO name while departing from his method and philosophy. He gave oil away for free and urged DIY production. The modern industry commercialized what he distributed freely—whether that’s improvement (quality control, testing) or betrayal (profit extraction) depends on perspective.

What isn’t disputed: modern RSO has evolved substantially. The products we offer represent that evolution, solving problems that limited Simpson’s original vision.

Traditional RSO vs. modern formulated RSO

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by heat	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets (553 mg/mL)
Lab testing	Not available	Full panel testing for potency, terpenes, pesticides, heavy metals, residual solvents, microbes
Residual solvents	Significant risk with naphtha	Controlled and tested—solvent-free production
Dosing precision	Approximate syringe-based	Measured per mL with graduated dropper (0.1 mL increments)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s formulas diverge from traditional RSO

Multi-cannabinoid approach. Traditional RSO relied on whatever single strain was available. Our formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited.

Terpene preservation and addition. Traditional RSO had essentially no terpene content. We include live terpenes at 5% with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level.

THCa as a separate ingredient. Traditional RSO fully decarboxylated everything. Our sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that’s lost when THCa converts to THC.

Reduced delta-9 THC dominance. Traditional RSO was 60-90% delta-9 THC. Our sublingual formula uses delta-9 THC at only 90 mg while distributing the remaining cannabinoid content across six other compounds, reflecting the broader cannabinoid research landscape.

Product format innovation. Simpson envisioned only oral oil. We offer both 30 mL sublingual oil and 1-gram vape cartridge, acknowledging that different delivery routes have different pharmacokinetic profiles.

Solvent safety and extraction evolution

Traditional RSO used naphtha or isopropyl alcohol—neither food-grade. Naphtha contains benzene, toluene, and other toxic compounds. Incomplete purging is difficult to verify without lab testing.

Modern cannabis extraction uses food-grade ethanol or supercritical CO₂, allowing complete solvent removal and validated testing via headspace gas chromatography. This is one of the most straightforward improvements over traditional RSO.

The decarboxylation question

Traditional RSO was fully decarboxylated. The rice cooker heat converted all THCa to delta-9 THC, losing acidic cannabinoids as distinct compounds.

Our sublingual formula preserves THCa at 1,500 mg. The distinction is legally significant: THCa is Farm Bill compliant at sale because it hasn’t been converted to delta-9 THC. Customers can decarboxylate at home by heating oil at 260°F for 45-60 minutes, converting 1,500 mg THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, this yields ~1,405 mg total delta-9 THC—giving psychoactive potency comparable to traditional illegal RSO entirely at customer discretion.

Terpene loss in traditional RSO

Terpenes volatize at relatively low temperatures (21-157°C). Traditional RSO’s solvent extraction and high-heat evaporation destroyed terpenes, making it essentially a cannabinoid-only product.

Our formulas specify live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. The entourage-effect literature provides theoretical framework for why preserving terpenes alongside cannabinoids may matter pharmacologically.

Evidence standards then and now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. His evidence was anecdotal, production unstandardized, claims untested. The cannabis underground was the only access point.

This document applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews, institutional summaries, then preclinical literature. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. We honor RSO’s historical origin while committing to modern cannabinoid science standards.

Simpson’s protocol vs. modern dosing considerations

Simpson’s protocol was designed around crude, single-strain extract. Comparing it to modern standardized multi-cannabinoid formulations isn’t straightforward—products are fundamentally different.

Key differences:

• Cannabinoid concentration: Our sublingual formula delivers 553 mg total active cannabinoids per mL. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios: Simpson’s oil was 60-90% delta-9 THC. Our formula distributes 16,590 mg across seven compounds.
• Terpene presence: Simpson’s oil had no terpenes. Ours includes 5% live terpenes.
• Delta-9 THC exposure: Simpson’s protocol at peak delivered ~600-900 mg delta-9 THC daily. Our sublingual formula contains only 90 mg delta-9 THC in the entire 30 mL bottle.

Future dosing guidance for our products should be developed independently of Simpson’s protocol, informed by per-compound evidence and responsible titration principles.

About OilWell Cannabis and the OilWell RSO Formula

The origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen offers vibrant culture but limited opportunities outside retail and healthcare. Reynosa is an industrial hub plagued by cartel violence.

Colin’s childhood was marked by hustling to transport items across the border for various groups. Those experiences exposed him to complexities and dangers. Many of his best friends have been killed or imprisoned. By sixteen, he had to leave home for good.

Despite dangers, Colin focused on cannabis—not harder substances. He saw it as safer and more beneficial. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in shadows, then transitioned to legal business.

Colin later became a formally trained software engineer, doing custom development for Baylor College of Medicine—one of the most prestigious medical institutions in the Texas Medical Center. That combination of deep cannabis knowledge plus medical-grade technical precision defines OilWell’s approach.

Bentley’s story—the foundation

The company’s origin begins with a dog named Bentley. Bentley was family, a companion through Colin’s toughest times. When Bentley fell seriously ill, veterinarians recommended euthanasia. Bentley was paralyzed in his back legs, and pain medications would destroy his organs.

Giving up wasn’t an option. In a desperate search for alternatives, Colin stumbled upon CBD through a question that changed everything: “You’ve moved how many tons of weed and you’ve never heard of CBD?” asked rescue worker Jessica.

Colin learned to create CBD golden paste for pets. It wasn’t a cure—it was hope. That hope delivered what veterinary medicine said was impossible: Bentley walked over to Colin and brought him his ball to play. From paralyzed and facing euthanasia to fetching his ball. Dogs don’t respond to placebo; this was cannabinoid medicine doing what pharmaceuticals couldn’t.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every condition Bentley faced:

• Neurodegeneration: led to understanding CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection
• Dementia: led to CBC’s role in neurogenesis
• Glaucoma: led to THC’s CB1 agonism for intraocular pressure reduction
• Arthritis: led to multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene simultaneously

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into cannabis beyond getting high. It became a mission to create real solutions that alleviate pain and suffering—for pets and people. Bentley’s story drives OilWell’s commitment to quality, innovation, and compassionate care.

Colin’s personal journey—PTSD and benzo addiction

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to quit Xanax, he did it cold turkey—a notoriously difficult and dangerous feat—using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula was created during midnight experiments while fighting benzo withdrawal. To ensure quick relief, OilWell also offers Peace Gummies in vape form, which Colin personally uses to manage insomnia and severe PTSD. This isn’t theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills don’t.

Doctors using our formulas

Over time, the therapeutic benefits Colin discovered through Bentley became the core of his work. He has developed formulas that doctors use for Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been making cannabis accessible and effective for everyone—including vegans, diabetics, and those with specific health needs.

ABC13 media recognition

ABC13 KTRK Houston featured OilWell Cannabis in seven comprehensive news segments from 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert in America’s fourth-largest city.

His quote from the first ABC13 feature in September 2019 captures our philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Current operations

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). We’ve been operating since 2019, generate approximately $1 million in annual revenue, maintain a near-5.0 Google rating, and are Texas DSHS licensed. Our products aren’t mass-produced—they’re carefully crafted with personal touch. All artwork, formulations, and packaging are created in-house in Houston.

The OilWell RSO philosophy

Our RSO is not traditional Rick Simpson Oil. It’s a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in deliberate, evidence-motivated ways.

Four core principles:

1. Accessibility over gatekeeping. No medical card required. Anyone 21+ can purchase. We ship nationwide and internationally. Simpson believed medicine should be accessible; we built a legal distribution model that makes that real.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their medicine; we engineered a product that puts that control in your hands through chemistry.

3. Open-source formulas. We publish our complete formulas publicly—every cannabinoid, every milligram, every percentage—so anyone who can’t afford the product can source ingredients and make their own. Simpson gave his oil away free and taught people to make it; we adapted that ethos for the modern marketplace.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section in this document represents our commitment to honest education about what science actually says. Simpson operated without peer-reviewed literature; we have that access and use it to distinguish what’s well-supported from what’s overstated.

Farm Bill compliance and the THCa legal framework

The 2018 Farm Bill legalized hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This is the foundation of our product design.

Our RSO Sublingual Oil contains only 90 mg of delta-9 THC in the entire 30 mL bottle—3 mg per mL—well under the 0.3% threshold. All cannabinoids are hemp-derived. The product is legal under federal law and in most states.

THCa is legally distinct. THCa (tetrahydrocannabinolic acid) is the acidic, non-psychoactive precursor to delta-9 THC. It is Farm Bill compliant at sale because it hasn’t been converted to delta-9 THC.

You can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500 mg THCa into ~1,315 mg delta-9 THC. Combined with the existing 90 mg delta-9 THC, this yields ~1,405 mg total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase.

This means the same product functions as non-psychoactive anti-inflammatory (used raw) or full-potency psychoactive medicine (after home decarboxylation). You control the decision. The product is legal everywhere all component cannabinoids are legal, enabling international shipping.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with local laws. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal risk.

Open-source formulas—why we publish everything

We publish our complete RSO formulas publicly so anyone who can’t afford our products ($129.99 for sublingual oil, $49.99 for vape cartridge) can source ingredients and make their own. The formulas in the RSO Sublingual Oil and RSO Vape Cartridge sections of this document are the open-source recipes.

This echoes Rick Simpson’s original ethos. He gave oil away free and taught people to make it. He never patented his method. We adapted that ethos: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and publish the complete recipe for those who want to make it themselves.

As Colin said on ABC13 in 2019: “I’m not trying to sell people snake oil… There’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of.”

The open-source philosophy started with Bentley. On our About Us page, we published the actual CBD golden paste recipe that saved Bentley’s life:

CBD golden paste recipe for pets—the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1-2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on pet size; consult veterinarian)

Instructions:

1. Mix turmeric and water in saucepan over low heat, stirring continuously until thick paste forms (7-10 minutes)
2. Add coconut oil and freshly ground black pepper, stir until thoroughly mixed
3. Cool and store in jar with lid in refrigerator for up to two weeks
4. Add small amount of CBD oil before giving to pet, adjusting dosage based on weight and needs

Serving suggestion: Mix small amount with pet’s food once or twice daily. Consult veterinarian before starting any new supplement regimen.

This recipe—published free, years before our RSO formulas—demonstrates that open-source is foundational behavior, not marketing strategy.

The decarboxylation choice—patient-controlled potency

Traditional RSO was always fully decarboxylated—no choice about psychoactivity.

Our sublingual formula contains 1,500 mg THCa in its acidic, non-psychoactive form, creating three distinct usage options:

Option 1—Raw, no heat: All 1,500 mg stays as THCa—completely non-psychoactive. Provides anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. Compatible with work, driving, and daytime use with zero impairment.

Option 2—Fully activated, home decarboxylation: Heat oil at 260°F for 45-60 minutes in oven-safe glass container. Converts 1,500 mg THCa to ~1,315 mg delta-9 THC. Combined with existing 90 mg delta-9 THC, yields ~1,405 mg total delta-9 THC. At customer discretion, product can achieve psychoactive potency comparable to traditional high-THC RSO—100% legally. You can also transfer a controlled portion to a second container and decarboxylate only what you intend to use, preserving the remainder raw.

Option 3—Vape, auto-decarboxylation: Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids—fastest-onset RSO delivery available.

Conversion chemistry: THCa has molecular weight of 358.47 g/mol. The ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation, reflecting loss of CO₂ molecule during reaction.

This design puts potency decision entirely in your hands—aligning with Rick Simpson’s principle that patients should control their medicine, but implementing it through actual product chemistry.

Solvent-free production

Our RSO is not a traditional extraction product. It’s a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in controlled production. No naphtha, no isopropyl alcohol, no butane, no extraction solvents in finished product.

This eliminates residual solvent risk—one of the most significant safety concerns with traditional RSO, as discussed above.

We use organic MCT oil (medium-chain triglycerides) as carrier base. MCT oil is food-grade lipid carrier facilitating sublingual absorption and providing neutral taste—a significant improvement over traditional RSO’s tar-like consistency and solvent-residual odor.

Third-party lab testing covers cannabinoid potency, terpene profile, pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and through our website.

The broader OilWell product portfolio

Beyond RSO, we produce:

Asshole Peach—our most popular product. A carefully formulated experience providing euphoric, long-lasting sensation, particularly favored by veterans for PTSD and pain relief.

Peace Gummies—developed directly from Colin’s experience with PTSD and benzodiazepine addiction. Helped him quit Xanax cold turkey. Also available in vape form for quick relief—Colin personally uses it for insomnia and severe PTSD.

Custom creations—we design tailored products for specific cannabinoid ratios, delivery formats, or unique health circumstances, including formulations for vegans, diabetics, and those with specific dietary needs.

Two product formats

We offer RSO formula in two delivery formats, each designed for different use cases:

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg/mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise 0.1 mL dosing increments
• Onset: 15-45 minutes (sublingual absorption)
• Peak effects: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19% (partially bypasses first-pass liver metabolism)
• Approximately 40-60 doses per bottle depending on serving size

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1-2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35% (variable by inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400-450°F)

Complete RSO Guide—our full product guide with science, competitive analysis, protocols, and ordering information.

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive comparison—OilWell RSO vs. alternatives

OilWell RSO vs. Texas TCUP dispensary RSO (e.g., Texas Original)

Dimension	TCUP dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (~420 mg THC per 0.5g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Delivery	Must travel to physical dispensary	Same-day delivery Houston, nationwide and international shipping
Farm Bill compliant	No—state medical cannabis program	Yes—<0.3% delta-9 THC

OilWell RSO vs. hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	~950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to ~1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes—via THCa decarboxylation and delta-8 THC
Approximate price	$40-50	$129.99

Condition-specific usage context

Important disclaimer: These contexts are informed by cannabinoid research in the GENERAL KNOWLEDGE section and our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not substitutes for professional medical care. These products haven’t been evaluated by the FDA and aren’t intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, take medications, are pregnant or nursing, or have health concerns. Don’t operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5-1.0 mL sublingual ~1 hour before treatment
• Acute breakthrough nausea: 2-3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0-2.0 mL sublingual before bed (delivers 25-50 mg CBN)
• Evidence: delta-8 THC antiemetic, delta-9 THC nausea relief, CBD anxiolytic buffering

Chronic pain (fibromyalgia, arthritis, neuropathy)

• Daytime: 0.3-0.5 mL raw sublingual—anti-inflammatory without psychoactive impairment
• Nighttime: 0.5-1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence: CBD and delta-9 THC pain relief, caryophyllene CB2 activation, THCa COX-2 inhibition

Sleep support

• Before bed: 1.0-2.0 mL sublingual
• At 2.0 mL: delivers 50 mg CBN—the dosage investigated in 2024 sleep literature
• At 1.0 mL: delivers 25 mg CBN—above threshold associated with reduced sleep disturbance
• Evidence: CBN sleep studies, cannabis and sleep review literature

Anxiety and stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety without impairment
• Nighttime: 1.0 mL sublingual—full profile including CBN for sleep architecture
• Evidence: CBD anxiolytic evidence, CBG pharmacology, limonene entourage effects

General titration principle: Start low, go slow. Begin with 0.25-0.5 mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary by body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and global accessibility for Montezuma County

For Montezuma County residents: While we operate from Houston, Texas, we ship nationwide to all 50 states where Farm Bill-compliant products are legal—including Colorado. Montezuma County residents can order directly from our website and receive products via USPS Priority Mail (2-3 business days) or FedEx/UPS Ground (3-5 business days). All packages are discreet with no cannabis branding visible, include tracking, and use temperature-stable packaging for summer shipments. Signature-required options are available.

International shipping: We ship internationally to jurisdictions where hemp-derived products with <0.3% delta-9 THC are permitted. All international packages include full documentation, Certificates of Analysis, and receipts for customs. Customers are responsible for verifying legality in their jurisdiction and accept all customs and legal risk.

Important for Montezuma County context: Unlike Texas, Colorado has legal recreational dispensaries. However, our product offers something different: seven cannabinoids with precise ratios, THCa preservation for patient-controlled potency, and third-party testing that may exceed what’s available locally. For residents in more remote areas like Towaoc or Mancos, our direct shipping eliminates the drive to Cortez dispensaries.

Contact: (832) 416-2816 or [email protected]

How our formulas connect to the evidence

Every cannabinoid in our formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in the GENERAL KNOWLEDGE section below. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

The formulas published in this document are anchored to per-compound evidence summaries that explain what’s well-supported by human clinical data, what’s emerging, and what’s overstated. Where we make specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context.

We don’t exempt ourselves from the same evidence standards applied to the broader field. Our position—as stated by Colin Valencia in 2019—is that people deserve the best possible version of information so they can give it a fair shot and decide for themselves whether it’s right or wrong for them.

This document is that research foundation.

Media Recognition and Community Impact

Colin Valencia—Houston’s go-to cannabis authority

Between September 2019 and April 2023, ABC13 Houston (KTRK) featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers. No other Houston cannabis operator appears with that frequency or breadth.

Feature timeline and key moments

September 15, 2019—Texas CBD businesses booming
Colin’s foundational quote: “I’m not trying to sell people snake oil… There’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot.”

March 22, 2021—Entrepreneur creates direct-to-consumer business
Colin’s therapy quote: “Pain comes in a lot of different forms.” This established his role as an ecosystem builder helping other entrepreneurs.

May 24, 2021—What is Delta-8 THC
Colin’s iconic honesty: “Maybe you want to get high.” This investigative feature balanced his unapologetic stance with medical caution and regulatory advocacy.

August 20, 2021—COVID vaccine giveaway
We gave away 1,000 special edition caviar pre-rolls (~$35,000 in product) to encourage vaccination. We coordinated with the city of Houston—no political strings attached, just community health action.

October 19, 2021—Texas ban over Delta-8
When Texas DSHS classified Delta-8 as Schedule I overnight, Colin proactively removed all products before enforcement and warned other operators who were unknowingly shipping Schedule I narcotics—ethical leadership during crisis.

October 7, 2022—Biden marijuana pardon
The article revealed Colin has personally faced marijuana possession charges: “You face challenges with housing, loans, and banking… I would love to see people not get hurt for this anymore.” This personal history transforms the entire media record—every quote carries additional weight.

April 21, 2023—Marijuana industry getting creative
Colin’s “Renaissance” framing: “Right now is actually a pretty important time that should be enjoyed now.” This completed a four-year arc, positioning OilWell at the frontier of the industry.

Complete index of Colin’s quotes across all features

All 13 quotes appear in chronological order in the original document, demonstrating consistency across four years of media coverage.

Key facts from media record

• OilWell operates from southwest Houston at 810 Richmond Avenue
• Products sold at HydroShack Hydroponics on West 20th Street in The Heights
• We partnered with The Game on special edition Delta-8 caviar comet rock pre-rolls
• We gave away ~$35,000 in product for COVID vaccination
• We contacted city of Houston to coordinate vaccination efforts
• Colin proactively removed Delta-8 products before enforcement began
• We tried to warn other operators who were unknowingly shipping Schedule I narcotics
• Colin has personal marijuana conviction history (revealed in Biden pardon feature)
• We were preparing to debut a CBD vending machine in 2022

The through-line

These seven features reveal five themes:

1. Consistency across years—ABC13 returned to Colin through every industry shift
2. Breadth of expertise—spanning business, law, medicine, politics, and community health
3. Community action—$35,000 vaccine giveaway, proactive Delta-8 removal, warning other operators
4. Personal stakes—Colin’s conviction history makes every quote more powerful
5. Evolution of language and role—from “local wholesaler” in 2019 to industry authority in 2023

This is recognition that cannot be purchased—it can only be earned.

General Knowledge

Research method and evidence weighting

We prioritize sources in this order: human clinical evidence, systematic reviews and meta-analyses, NIH and institutional summaries, then mechanistic or preclinical literature when human data are sparse. This matters because the evidence base is uneven—CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes depend more on reviews, animal work, and pharmacology [1]-[29].

Institutional baseline from NIH and related sources

• NCCIH states strongest established cannabinoid evidence is for rare epilepsies, chemo nausea/vomiting, and HIV/AIDS appetite/weight loss. Modest evidence exists for chronic pain and MS symptoms. Many claimed uses remain early-stage [1].
• FDA has not approved cannabis plant for medical use—only purified CBD (Epidiolex) and synthetic THC analogues (dronabinol/nabilone) [1].
• Safety concerns: impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, accidental pediatric exposure, contamination/labeling inaccuracy, THC-vape lung injury [1].
• Over-the-counter CBD products may differ from labels. CBD associated with decreased alertness, GI effects, liver abnormalities, and drug interactions [1].

Cannabinoids

CBD

• Evidence: Strongest human evidence in this formula set, especially as purified product [1]-[6]
• Best supported: Seizure disorders—clearest major-example indication acknowledged by institutional literature [1][2]
• Anxiety: 2024 systematic review of 316 participants found significant anxiolytic signal but stressed limited clinical sample—more trials needed [3]
• Pain: 2024 systematic review concluded promising but heterogeneous—trial quality limits broad analgesic claims [4]
• Sleep: 2023 review found literature methodologically weak, relying on nonvalidated subjective measures [5]
• Safety: 2023 meta-analysis found real signal for liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products and polypharmacy [6]
• Bottom line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence concentrated in specific indications rather than broad wellness claims [1]-[6]

CBG

• Evidence: Mostly review and preclinical; human evidence sparse [7][8]
• Pharmacology: Biosynthetic precursor with distinct pharmacology—interacts with cannabinoid receptors, alpha-2 adrenoceptors, 5-HT1A signaling [7]
• Research areas: Possible relevance to neurologic disorders, inflammatory bowel disease, antibacterial activity—primarily preclinical hypotheses [7][8]
• Caution: Being sold commercially while evidence base remains thin—claims frequently outrun science [7]
• Bottom line: Serious research topic, but should be described as promising minor cannabinoid with limited clinical validation [7][8]

Delta-8 THC

• Evidence: Pharmacologically relevant, psychoactive, much less clinically characterized than delta-9 THC [9]-[11]
• Comparative pharmacology: 2022 review concluded delta-8 and delta-9 have broadly similar PK/PD behavior. Delta-8 is partial CB1 agonist, less potent than delta-9, likely due to weaker CB1 affinity [9]
• Public health: 2023 scoping review found evidence base dominated by animal studies, chemistry, use reports, and public-health concerns rather than strong human trials. Noted adverse consequence reports and regulatory/product-quality concerns [10]
• Manufacturing: Interest tied to greater stability and easier synthesis relative to naturally scarce plant levels—product-byproduct and lab-testing questions matter [11]
• Bottom line: Psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many realize [9]-[11]

THCa

• Evidence: Important chemically/formulation-wise, but low on direct human therapeutic evidence [12]
• What it is: Acidic precursor of THC, may represent large share of THC-related content in raw plant material. Decarboxylates into THC during heating/storage [12]
• Psychoactivity: THCa itself doesn’t produce THC’s psychoactive effects, but distinction only holds if molecule stays acidic and isn’t substantially decarboxylated [12]
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities—not equivalent to established human outcomes [12]
• Bottom line: Highly relevant precursor whose interpretation depends heavily on route, temperature, processing, and storage. Any claim must account for possible conversion to THC [12]

Delta-9 THC

• Evidence: Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15]
• Best supported: NCCIH identifies relevance to chemo nausea/vomiting, HIV/AIDS appetite/weight loss, some MS and pain outcomes, while stressing many uses remain uncertain [1]
• Pain: 2022 systematic review found high-THC or comparable THC:CBD products may provide short-term pain benefit but increased dizziness, sedation, nausea, and discontinuation due to adverse events [13]
• Pharmacokinetics: Inhaled THC: seconds to minutes onset, peaks 15-30 minutes, tapers over few hours. Oral THC: later onset, later peak, longer duration—matters for benefit and overconsumption risk [14]
• Mental health risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, plus concerning signals for anxiety/depression in nontherapeutic settings [15]
• Broader safety: Anxiety/panic at high doses, tachycardia, blood pressure changes, dependency, withdrawal, pregnancy concerns, accidental pediatric exposure, vape-related lung injury [1][14][15]
• Bottom line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities [1][13]-[15]

CBN

• Evidence: Weak human evidence; marketing moved ahead of data [12][16][17]
• Reputation vs. reality: Widely marketed for sleep/sedation, but clinical support far thinner than market suggests [16][17]
• Best review: 2021 narrative review screened 99 human-study abstracts, reviewed 8 full-text articles, found no clinical trials using validated sleep questionnaires or polysomnography that could substantiate strong sleep-promoting claims [16]
• Broader sleep literature: 2024 updated review concluded cannabinoid sleep research still doesn’t match scale of real-world use—need for better-designed, adequately powered trials remains substantial [17]
• Chemical context: THC can degrade toward CBN under certain conditions, explaining why CBN discussed in aging/oxidized cannabis contexts [12]
• Bottom line: Clearest example where cultural reputation stronger than current clinical evidence base [16][17]

CBC

• Evidence: Emerging, intriguing, overwhelmingly preclinical or review-based [18][19]
• Pharmacology: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, receptor behavior relative to better-known cannabinoids—highlights antinociceptive, antibacterial, anti-seizure as interesting research targets [18]
• Older literature: Anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological/antiproliferative relevance—but not yet strong evidence for patient-facing claims [19]
• Safety caveat: 2024 CBC review explicitly notes over-the-counter CBC products being sold despite little evidence establishing clinical efficacy or safety [18]
• Bottom line: Scientifically credible minor cannabinoid deserving more research, not already-validated clinical active [18][19]

Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

• Evidence: Largely review and preclinical, with useful safety literature [20]-[22]
• Potential activity: 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory activities—but overwhelming share from nonhuman/non-cannabis literature [21]
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens important in patch-testing literature [22]
• Bottom line: Biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly supported in humans [20]-[22]

Myrcene

• Evidence: Mostly preclinical, very limited human evidence [20][23]
• Research summary: 2021 review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties and possible mechanisms, but explicitly states human studies lacking [23]
• Interpretation caution: Often invoked as proven sedating terpene explaining couch-lock or sleep effects—stronger claim than human evidence currently supports [20][23]
• Bottom line: Plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof [23]

Caryophyllene

• Evidence: Among most mechanistically interesting because of direct cannabinoid-system relevance, but still mostly preclinical [24]
• Why it stands out: 2021 focused review describes beta-caryophyllene as selective CB2 receptor agonist—unusual and especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms [24]
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective actions repeatedly discussed, but human clinical confirmation limited [24]
• Bottom line: Arguably strongest candidate for terpene with cannabinoid-system significance, but still shouldn’t be described as clinically proven for outcomes commonly attributed [24]

Pinene

• Evidence: Promising preclinical literature, weak human clinical confirmation [20][25]
• Brain-health framing: 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized evidence mostly preclinical and well-designed clinical trials lacking [25]
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts [20][25]
• Bottom line: Deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25]

Linalool

• Evidence: Similar to pinene—substantial preclinical interest, limited direct clinical confirmation [20][22][25][26]
• Research summary: Repeatedly discussed in relation to stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation while emphasizing lack of robust human trials [25]
• Additional literature: Separate review discusses possible antidepressant mechanisms and neuropharmacologic relevance, but remains translational rather than definitive clinical story [26]
• Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature [22]
• Bottom line: Scientifically credible as bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26]

Humulene

• Evidence: Translationally interesting, but still early [20][27]
• Scoping-review findings: 2024 scoping review analyzed 340 articles, found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27]
• Interpretation caution: Findings valuable for hypothesis generation, but don’t yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27]
• Bottom line: One of more interesting terpene research targets, but remains far from clinically settled [27]

Terpinolene

• Evidence: One of least clinically characterized terpenes in this file [20][28]
• Systematic-review findings: 2021 review screened 2,449 records, included 57 studies, concluded terpinolene has range of reported biological effects but evidence base still dominated by in silico, in vitro, and animal studies rather than human trials [28]
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects [20]
• Bottom line: Biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28]

Research limits and interpretation

1. Evidence base is highly uneven. CBD and delta-9 THC support most detailed human-facing statements; rest require more caution [1]-[29]
2. Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data aren’t interchangeable. Common error is letting evidence from one category stand in for another
3. Minor cannabinoids and terpenes are commercially interesting precisely because underexplored, but that also means claims around them often become inflated
4. Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14]
5. For THCa especially, chemistry is destiny: Storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids like THC [12]

Common overstatements to avoid

• Overstatement: CBN is clinically proven sleep cannabinoid
  More accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17]
• Overstatement: Myrcene is proven human sedative that reliably explains couch-lock
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23]
• Overstatement: Terpenes in general have proven entourage effects in patients
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29]
• Overstatement: THCa is always nonpsychoactive
  More accurate: THCa itself isn’t THC, but heating and processing can convert THCa into THC, changing effective exposure [12]
• Overstatement: Delta-8 THC is safe because it’s hemp-derived
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11]

Practical takeaways for formulas in this document

• Most evidence-developed actives: CBD and delta-9 THC
• Delta-8 THC isn’t trivial or purely mild—it’s psychoactive cannabinoid with less robust safety/efficacy characterization than delta-9 THC
• THCa meaningfully changes with processing and shouldn’t be interpreted same way in raw, gently handled, and heated formats
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC
• Listed terpenes likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported

References [1]-[29]

Full list of 29 peer-reviewed citations appears in the original document, providing source evaluation context for every compound-level claim in this file.

RSO Sublingual Oil Formula

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5%
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Base: Organic MCT oil
• Dosing: Graduated dropper with 0.1 mL increments
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Bioavailability: 13-19%

RSO Vape Cartridge Formula

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge
• Battery: 510-thread universal compatibility
• Onset: 1-2 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%

Terpene Profile (Both Products)

• Limonene: Citrus-bright
• Myrcene: (No descriptor in original—earthy, musky, clove-like is typical)
• Caryophyllene: Pepper/spice (β-caryophyllene)
• Pinene: Forest-fresh
• Linalool: Floral, lavender
• Humulene: Earthy, woody
• Terpinolene: Piney, fruity, sparkling

Final thoughts for Montezuma County:

We know life in the Four Corners region comes with unique challenges. The distance to major medical centers means many of you are managing health conditions with limited local resources. The agricultural heritage means you understand the value of natural medicine, but you also understand the importance of precision and quality. The veteran community here deserves options that work when pharmaceuticals fail. The Ute Mountain Ute Tribe’s sovereignty reminds us that cannabis has been used as medicine for far longer than it’s been illegal.

Our RSO formulas aren’t magic, and we won’t insult your intelligence by pretending otherwise. What they are is the most thoughtful, transparent, and evidence-informed multi-cannabinoid oil we can make—born from a decade of formulation work that started with saving a paralyzed dog and continued through one founder’s own battle with PTSD and benzo addiction.

For Montezuma County residents considering RSO, whether you’re in Cortez, Dolores, Mancos, Towaoc, or out on ranch land between them, we offer something different: complete formula transparency, patient-controlled potency, and the honest science you need to make an informed decision. No medical card required. No gatekeeping. Just the product, the recipe, and the evidence—to give it a fair shot and decide if it’s right or wrong for you.

Contact us:

• Phone: (832) 416-2816
• Email: [email protected]
• Website: https://oilwellcbd.com/
• Instagram: @oilwellcbd
• Address: 810 Richmond Ave, Houston, TX 77006

Age requirement: 21+ for all RSO products
THC compliance: All products contain <0.3% delta-9 THC; Farm Bill compliant; hemp-derived cannabinoids
FDA disclaimer: Not evaluated by FDA; not intended to diagnose, treat, cure, or prevent disease; consult healthcare provider; individual results may vary
Safety warnings: May cause drowsiness or impairment; do not operate vehicles or machinery; consult physician if pregnant or nursing; keep out of reach of children
Legal responsibility: Customer responsible for checking local laws; company assumes no legal responsibility for customer’s use or decarboxylation decisions; void where prohibited

This content is provided for educational purposes. Always consult with qualified healthcare providers about your specific medical needs. The information presented here reflects the current state of cannabinoid research and our specific product formulations as of March 2026.